Affinity DataKi: 4nMAssay Description:Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarizat...More data for this Ligand-Target Pair
Affinity DataKi: 5nMAssay Description:Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarizat...More data for this Ligand-Target Pair
TargetHeat shock protein 75 kDa, mitochondrial(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 16nMAssay Description:Binding affinity to human recombinant TRAP1 after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetHeat shock protein 75 kDa, mitochondrial(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 62nMAssay Description:Binding affinity to human recombinant TRAP1 after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataKi: 176nMAssay Description:Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarizat...More data for this Ligand-Target Pair
TargetHeat shock protein 75 kDa, mitochondrial(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 326nMAssay Description:Binding affinity to human recombinant TRAP1 after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataKi: 375nMAssay Description:Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarizat...More data for this Ligand-Target Pair
Affinity DataKi: 484nMAssay Description:Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarizat...More data for this Ligand-Target Pair
TargetHeat shock protein 75 kDa, mitochondrial(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 791nMAssay Description:Binding affinity to human recombinant TRAP1 after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetHeat shock protein 75 kDa, mitochondrial(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 1.20E+3nMAssay Description:Binding affinity to human recombinant TRAP1 after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataKi: 2.65E+3nMAssay Description:Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarizat...More data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of ELOVL1 in Het Female 1 patient-derived human lymphocyte assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular...More data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of ELOVL1 in Het Female 2 patient-derived human lymphocyte assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular...More data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of ELOVL1 in human microglia assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of ELOVL1 in human HEK293 cells assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of ELOVL1 in CALD patient-derived human lymphocyte assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of ELOVL1 in AMN 2 patient-derived fibroblast assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of ELOVL1 in CALD patient-derived human fibroblast assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 38nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 43nMAssay Description:Inhibition of ELOVL1 in AMN 1 patient-derived fibroblast assessed as reduction of C26:0 VLCFA synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 60nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 70nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 80nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 110nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 110nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 170nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 170nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 190nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 210nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 260nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 280nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 310nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 340nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of ELOVL1 in human HEK2936E cells assessed as reduction of C26:0 LPC synthesis incubated for 48 hrs by cellular assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of ELOVL1 (unknown origin) using C22-acyl-CoA as substrate by radiometric enzyme assayMore data for this Ligand-Target Pair
TargetElongation of very long chain fatty acids protein 1(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Inhibition of ELOVL1 (unknown origin) using C22-acyl-CoA as substrate by radiometric enzyme assayMore data for this Ligand-Target Pair